Abstract
GSK is one of the leading ethical pharmaceutical companies in the industry
with an estimated seven per cent share of the world' s pharmaceutical market.
This report provides a full review of the company' s activities together with
sales forecasts for key products to 2010.
Headquartered in the UK and with operations based in the US, GSK is one of the
leading ethical pharmaceutical companies in the industry with an estimated
seven per cent share of the world' s pharmaceutical market. GlaxoSmithKline was
formed in 2000 as a result of the merger of Glaxo Wellcome and SmithKline
Beecham. In 2005, it was the world' s second largest research-based
pharmaceutical company based on pharmaceutical sales.
GSK employs over 100,000 people in 116 countries, with over 40,000 of these in
sales and marketing, the largest sales force in the industry. GSK has a broad
portfolio, with projects in the fields of respiratory, central nervous system,
anti-infectives, metabolic disorders, oncology, cardiovascular and urogenital.
In addition, GSK has an extensive vaccines portfolio. According to GSK, it
supplied one quarter of the world' s vaccines and by the end of 2005 and had a
further 25 in clinical development. The company has a leading position in
genomics/genetics and new drug discovery technologies. GSK also has a Consumer
Healthcare portfolio comprising over-the-counter medicines, oral care products
and nutritional healthcare drinks, all of which are among the market leaders.
Current Growth Drivers
GSK' s key growth drivers in 2005 were:
Advair which maintained its strong growth in the US and Europe with
sales of £1,687 million and £1,033 million, respectively.
Flonase for perennial rhinitis also showed strong growth in the US.
Wellbutrin XL performed exceptionally well, helping to offset the
decline in sales of the immediate-release products due to generic competition.
Antivirals grew by 10 per cent, with HIV products up by 2 per cent.
Sales of Valtrex, for herpes, grew by 26 per cent driven by patients switching
to suppression therapy.
Sales of Avandia/Avandamet increased by 14 per cent, whilst
antibacterial sales declined by 27 per cent as a result of generic competition
that began in the third quarter 2002. Coreg sales increased by 33 per cent to
£568 million reflecting the benefit of its wide range of indications.
Vaccines also performed well in 2005, growing by 26 per cent,
reflecting a strong performance of Pediarix and Fluarix.
View Cart
